Terms: = Ovarian cancer AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132
27 results:
1. β-Sitosterol targets ASS1 for Nrf2 ubiquitin-dependent degradation, inducing ROS-mediated apoptosis via the PTEN/PI3K/AKT signaling pathway in ovarian cancer.
Wang H; Liu J; Zhang Z; Peng J; Wang Z; Yang L; Wang X; Hu S; Hong L
Free Radic Biol Med; 2024 Mar; 214():137-157. PubMed ID: 38364944
[TBL] [Abstract] [Full Text] [Related]
2. A Morpholine Derivative N-(4-Morpholinomethylene)ethanesulfonamide Induces Ferroptosis in Tumor Cells by Targeting NRF2.
Sun B; Zhang L; Wu B; Luo X
Biol Pharm Bull; 2024 Feb; 47(2):417-426. PubMed ID: 38296488
[TBL] [Abstract] [Full Text] [Related]
3. Interplay of oxidative stress, cellular communication and signaling pathways in cancer.
Iqbal MJ; Kabeer A; Abbas Z; Siddiqui HA; Calina D; Sharifi-Rad J; Cho WC
Cell Commun Signal; 2024 Jan; 22(1):7. PubMed ID: 38167159
[TBL] [Abstract] [Full Text] [Related]
4. Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors.
Wang X; Su S; Zhu Y; Cheng X; Cheng C; Chen L; Lei A; Zhang L; Xu Y; Ye D; Zhang Y; Li W; Zhang J
Nat Commun; 2023 Sep; 14(1):5778. PubMed ID: 37723178
[TBL] [Abstract] [Full Text] [Related]
5. Role of the Nrf2 Signaling Pathway in ovarian Aging: Potential Mechanism and Protective Strategies.
Gao X; Wang B; Huang Y; Wu M; Li Y; Li Y; Zhu X; Wu M
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686132
[TBL] [Abstract] [Full Text] [Related]
6. Natural and synthetic compounds in ovarian cancer: A focus on NRF2/keap1 pathway.
Tossetta G; Marzioni D
Pharmacol Res; 2022 Sep; 183():106365. PubMed ID: 35901941
[TBL] [Abstract] [Full Text] [Related]
7. Dihydrotanshinone I inhibits ovarian tumor growth by activating oxidative stress through keap1-mediated Nrf2 ubiquitination degradation.
Sun C; Han B; Zhai Y; Zhao H; Li X; Qian J; Hao X; Liu Q; Shen J; Kai G
Free Radic Biol Med; 2022 Feb; 180():220-235. PubMed ID: 35074488
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.
Wu Z; Tao H; Zhang S; Wang X; Ma J; Li R; Liu Z; Wang J; Cui P; Chen S; Di H; Huang Z; Zheng X; Hu Y
Cancer Immunol Immunother; 2021 Oct; 70(10):2971-2980. PubMed ID: 33740125
[TBL] [Abstract] [Full Text] [Related]
9. KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma.
Saglam O; Tang Z; Tang G; Medeiros LJ; Toruner GA
PLoS One; 2020; 15(9):e0238477. PubMed ID: 32877461
[TBL] [Abstract] [Full Text] [Related]
10. MicroRNAs as regulators of VEGFA and NFE2L2 in cancer.
Cuzziol CI; Castanhole-Nunes MMU; Pavarino ÉC; Goloni-Bertollo EM
Gene; 2020 Oct; 759():144994. PubMed ID: 32721475
[TBL] [Abstract] [Full Text] [Related]
11. Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism.
Cucci MA; Grattarola M; Dianzani C; Damia G; Ricci F; Roetto A; Trotta F; Barrera G; Pizzimenti S
Free Radic Biol Med; 2020 Apr; 150():125-135. PubMed ID: 32101771
[TBL] [Abstract] [Full Text] [Related]
12. Effects of cigarette smoke extracts on apoptosis and oxidative stress in two models of ovarian cancer in vitro.
Kim CW; Go RE; Hwang KA; Bae ON; Lee K; Choi KC
Toxicol In Vitro; 2018 Oct; 52():161-169. PubMed ID: 29894801
[TBL] [Abstract] [Full Text] [Related]
13. CCRK is a novel signalling hub exploitable in cancer immunotherapy.
Mok MT; Zhou J; Tang W; Zeng X; Oliver AW; Ward SE; Cheng AS
Pharmacol Ther; 2018 Jun; 186():138-151. PubMed ID: 29360538
[TBL] [Abstract] [Full Text] [Related]
14. Expression Patterns of Nrf2 and keap1 in ovarian cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival.
Cho HY; Kim K; Kim YB; Kim H; No JH
Int J Gynecol Cancer; 2017 Mar; 27(3):412-419. PubMed ID: 28129239
[TBL] [Abstract] [Full Text] [Related]
15. cancer Stem Cell Properties as Factors Predictive of Chemoresistance in Neoadjuvantly-treated Patients with ovarian cancer.
Pylväs-Eerola M; Liakka A; Puistola U; Koivunen J; Karihtala P
Anticancer Res; 2016 Jul; 36(7):3425-31. PubMed ID: 27354603
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic and predictive values of Nrf2, keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract] [Full Text] [Related]
17. The role of the catecholic and the electrophilic moieties of caffeic acid in Nrf2/keap1 pathway activation in ovarian carcinoma cell lines.
Sirota R; Gibson D; Kohen R
Redox Biol; 2015; 4():48-59. PubMed ID: 25498967
[TBL] [Abstract] [Full Text] [Related]
18. Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells.
Khalil HS; Goltsov A; Langdon SP; Harrison DJ; Bown J; Deeni Y
J Biotechnol; 2015 May; 202():12-30. PubMed ID: 25449014
[TBL] [Abstract] [Full Text] [Related]
19. Nrf2, the master redox switch: the Achilles' heel of ovarian cancer?
van der Wijst MG; Brown R; Rots MG
Biochim Biophys Acta; 2014 Dec; 1846(2):494-509. PubMed ID: 25270772
[TBL] [Abstract] [Full Text] [Related]
20. p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the keap1-Nrf2-ARE system.
Xia M; Yu H; Gu S; Xu Y; Su J; Li H; Kang J; Cui M
Int J Oncol; 2014 Dec; 45(6):2341-8. PubMed ID: 25269472
[TBL] [Abstract] [Full Text] [Related]
[Next]
